Corcept Therapeutics Terminates Material Agreement
Ticker: CORT · Form: 8-K · Filed: Oct 14, 2025 · CIK: 1088856
Sentiment: neutral
Topics: agreement-termination, material-agreement
TL;DR
Corcept terminated a big deal, filing shows.
AI Summary
Corcept Therapeutics Inc. filed an 8-K on October 14, 2025, reporting the termination of a material definitive agreement. The filing does not provide specific details on the agreement terminated or the parties involved.
Why It Matters
The termination of a material definitive agreement can signal a significant shift in business relationships or strategic direction for Corcept Therapeutics.
Risk Assessment
Risk Level: medium — Termination of a material definitive agreement can indicate potential business disruptions or strategic changes that may impact the company's future performance.
Key Players & Entities
- Corcept Therapeutics Inc. (company) — Registrant
- October 10, 2025 (date) — Earliest event reported
- October 14, 2025 (date) — Date of Report
- 101 Redwood Shores Parkway, Redwood City, CA 94065 (location) — Principal Executive Offices
FAQ
What was the material definitive agreement that Corcept Therapeutics terminated?
The filing does not specify the details of the material definitive agreement that was terminated.
When was the termination of the material definitive agreement effective?
The filing indicates that October 10, 2025, is the date of the earliest event reported, which is related to the termination of a material definitive agreement.
Who were the parties involved in the terminated material definitive agreement?
The filing does not disclose the names of the parties involved in the terminated agreement.
What is the business address of Corcept Therapeutics Inc.?
The business address of Corcept Therapeutics Inc. is 101 Redwood Shores Parkway, Redwood City, CA 94065.
What is the primary business of Corcept Therapeutics Inc.?
Corcept Therapeutics Inc. is in the Pharmaceutical Preparations industry (SIC code 2834).
Filing Stats: 668 words · 3 min read · ~2 pages · Grade level 12.3 · Accepted 2025-10-14 06:02:00
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value CORT The Nasdaq Stock Mar
Filing Documents
- d61706d8k.htm (8-K) — 26KB
- 0001193125-25-237834.txt ( ) — 134KB
- cort-20251010.xsd (EX-101.SCH) — 3KB
- cort-20251010_lab.xml (EX-101.LAB) — 17KB
- cort-20251010_pre.xml (EX-101.PRE) — 11KB
- d61706d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CORCEPT THERAPEUTICS INCORPORATED Date: October 14, 2025 By: /s/ Atabak Mokari Name: Atabak Mokari Title: Chief Financial Officer